株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸癌 : パイプライン製品の分析

Colon Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229732
出版日 ページ情報 英文 722 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.92円で換算しております。
Back to Top
大腸癌 : パイプライン製品の分析 Colon Cancer - Pipeline Review, H2 2016
出版日: 2016年12月30日 ページ情報: 英文 722 Pages
概要

大腸・結腸直腸癌は、大腸(結腸)または直腸(大腸の最終部分)に発症する癌です。単一の原因は特定できません。ほぼすべての大腸癌は、非癌性(良性)のポリープに始まり、ゆっくりと癌に進行します。多くの場合、症状はありません。腹痛や下腹部の圧痛、血便、下痢、便秘、または排便習慣の変化、原因不明の体重減少などが見られます。治療には、外科手術、放射線療法、化学療法などが含まれます。

当レポートでは、大腸癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

大腸癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8848IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H2 2016, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 35, 3, 155 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 46 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Colon Cancer Overview
  • Therapeutics Development
  • Colon Cancer - Therapeutics under Development by Companies
  • Colon Cancer - Therapeutics under Investigation by Universities/Institutes
  • Colon Cancer - Pipeline Products Glance
  • Colon Cancer - Products under Development by Companies
  • Colon Cancer - Products under Investigation by Universities/Institutes
  • Colon Cancer - Companies Involved in Therapeutics Development
  • Colon Cancer - Therapeutics Assessment
  • Drug Profiles
  • Colon Cancer - Dormant Projects
  • Colon Cancer - Discontinued Products
  • Colon Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Colon Cancer, H2 2016
  • Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Adamed Sp z oo, H2 2016
  • Colon Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
  • Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016
  • Colon Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Affimed GmbH, H2 2016
  • Colon Cancer - Pipeline by Agenus Inc, H2 2016
  • Colon Cancer - Pipeline by AGV Discovery SAS, H2 2016
  • Colon Cancer - Pipeline by AIMM Therapeutics BV, H2 2016
  • Colon Cancer - Pipeline by Almac Discovery Ltd, H2 2016
  • Colon Cancer - Pipeline by Ambrx Inc, H2 2016
  • Colon Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016
  • Colon Cancer - Pipeline by AndroScience Corp, H2 2016
  • Colon Cancer - Pipeline by Aphios Corp, H2 2016
  • Colon Cancer - Pipeline by Aposense Ltd, H2 2016
  • Colon Cancer - Pipeline by Aptose Biosciences Inc, H2 2016
  • Colon Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Colon Cancer - Pipeline by BCN Biosciences LLC, H2 2016
  • Colon Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016
  • Colon Cancer - Pipeline by BioCancell Ltd, H2 2016
  • Colon Cancer - Pipeline by Biogazelle NV, H2 2016
  • Colon Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016
  • Colon Cancer - Pipeline by Blirt SA, H2 2016
  • Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016
  • Colon Cancer - Pipeline by Celprogen Inc, H2 2016
  • Colon Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
  • Colon Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2016
  • Colon Cancer - Pipeline by CZ BioMed Corp, H2 2016
  • Colon Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Colon Cancer - Pipeline by DEKK-TEC Inc, H2 2016
  • Colon Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Colon Cancer - Pipeline by EntreChem SL, H2 2016
  • Colon Cancer - Pipeline by EnzymeBioSystems, H2 2016
  • Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Colon Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2016
  • Colon Cancer - Pipeline by GlycoMimetics Inc, H2 2016
  • Colon Cancer - Pipeline by Grunenthal GmbH, H2 2016
  • Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Hamlet Pharma AB, H2 2016
  • Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Colon Cancer - Pipeline by Helix BioPharma Corp, H2 2016
  • Colon Cancer - Pipeline by Histogen Inc, H2 2016
  • Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2016
  • Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Immunome Inc, H2 2016
  • Colon Cancer - Pipeline by Immunomedics Inc, H2 2016
  • Colon Cancer - Pipeline by Immunotope Inc, H2 2016
  • Colon Cancer - Pipeline by Immupharma Plc, H2 2016
  • Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Incuron LLC, H2 2016
  • Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016
  • Colon Cancer - Pipeline by Innopharmax Inc, H2 2016
  • Colon Cancer - Pipeline by Intezyne Technologies Inc, H2 2016
  • Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016
  • Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016
  • Colon Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016
  • Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
  • Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Colon Cancer - Pipeline by Lipocure Ltd, H2 2016
  • Colon Cancer - Pipeline by Lupin Ltd, H2 2016
  • Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H2 2016
  • Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016
  • Colon Cancer - Pipeline by MacroGenics Inc, H2 2016
  • Colon Cancer - Pipeline by MaxiVAX SA, H2 2016
  • Colon Cancer - Pipeline by Meabco A/S, H2 2016
  • Colon Cancer - Pipeline by Medicenna Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Microlin Bio, Inc., H2 2016
  • Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2016
  • Colon Cancer - Pipeline by MolMed SpA, H2 2016
  • Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2016
  • Colon Cancer - Pipeline by Multimmune GmbH, H2 2016
  • Colon Cancer - Pipeline by NormOxys Inc, H2 2016
  • Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Novartis AG, H2 2016
  • Colon Cancer - Pipeline by Omeros Corp, H2 2016
  • Colon Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Oncovir Inc, H2 2016
  • Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Colon Cancer - Pipeline by Orega Biotech SAS, H2 2016
  • Colon Cancer - Pipeline by OSE Immunotherapeutics, H2 2016
  • Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Patrys Ltd, H2 2016
  • Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H2 2016
  • Colon Cancer - Pipeline by Pharminox Ltd, H2 2016
  • Colon Cancer - Pipeline by Philogen SpA, H2 2016
  • Colon Cancer - Pipeline by Pique Therapeutics, H2 2016
  • Colon Cancer - Pipeline by Plexxikon Inc, H2 2016
  • Colon Cancer - Pipeline by ProNAi Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Provecs Medical GmbH, H2 2016
  • Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Qu Biologics Inc, H2 2016
  • Colon Cancer - Pipeline by Recce Pty Ltd, H2 2016
  • Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Rgenix Inc, H2 2016
  • Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2016
  • Colon Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016
  • Colon Cancer - Pipeline by Sellas Inc, H2 2016
  • Colon Cancer - Pipeline by Sigma-Tau SpA, H2 2016
  • Colon Cancer - Pipeline by Sirnaomics Inc, H2 2016
  • Colon Cancer - Pipeline by SOM Biotech SL, H2 2016
  • Colon Cancer - Pipeline by Somantix BV, H2 2016
  • Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016
  • Colon Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016
  • Colon Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016
  • Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H2 2016
  • Colon Cancer - Pipeline by TaiRx Inc, H2 2016
  • Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016
  • Colon Cancer - Pipeline by Takis Srl, H2 2016
  • Colon Cancer - Pipeline by Targovax ASA, H2 2016
  • Colon Cancer - Pipeline by Transgene Biotek Ltd, H2 2016
  • Colon Cancer - Pipeline by TVAX Biomedical Inc, H2 2016
  • Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2016
  • Colon Cancer - Pipeline by TyrNovo Ltd, H2 2016
  • Colon Cancer - Pipeline by Vaccinogen Inc, H2 2016
  • Colon Cancer - Pipeline by Vault Pharma Inc, H2 2016
  • Colon Cancer - Pipeline by Vaxenta Biotechnologies, H2 2016
  • Colon Cancer - Pipeline by Vaximm AG, H2 2016
  • Colon Cancer - Pipeline by VG Life Sciences Inc, H2 2016
  • Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H2 2016
  • Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016
  • Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Colon Cancer - Dormant Projects, H2 2016
  • Colon Cancer - Dormant Projects (Contd..1), H2 2016
  • Colon Cancer - Dormant Projects (Contd..2), H2 2016
  • Colon Cancer - Dormant Projects (Contd..3), H2 2016
  • Colon Cancer - Dormant Projects (Contd..4), H2 2016
  • Colon Cancer - Dormant Projects (Contd..5), H2 2016
  • Colon Cancer - Dormant Projects (Contd..6), H2 2016
  • Colon Cancer - Dormant Projects (Contd..7), H2 2016
  • Colon Cancer - Dormant Projects (Contd..8), H2 2016
  • Colon Cancer - Dormant Projects (Contd..9), H2 2016
  • Colon Cancer - Dormant Projects (Contd..10), H2 2016
  • Colon Cancer - Dormant Projects (Contd..11), H2 2016
  • Colon Cancer - Dormant Projects (Contd..12), H2 2016
  • Colon Cancer - Dormant Projects (Contd..13), H2 2016
  • Colon Cancer - Dormant Projects (Contd..14), H2 2016
  • Colon Cancer - Dormant Projects (Contd..15), H2 2016
  • Colon Cancer - Dormant Projects (Contd..16), H2 2016
  • Colon Cancer - Dormant Projects (Contd..17), H2 2016
  • Colon Cancer - Dormant Projects (Contd..18), H2 2016
  • Colon Cancer - Dormant Projects (Contd..19), H2 2016
  • Colon Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Colon Cancer, H2 2016
  • Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top